Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with SpironolactoneReportar como inadecuado




Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with Spironolactone - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Ophthalmology - Volume 2016 2016, Article ID 8491320, 6 pages -

Clinical Study

Instituto Oftalmológico Fernández-Vega, 33012 Oviedo, Spain

Instituto Universitario Fernández-Vega, Universidad de Oviedo, Oviedo, Spain

Fundación Oftalmológica de Santander FOSCAL, Floridablanca 681004, Colombia

Universidad Industrial de Santander, Bucaramanga 680002, Colombia

Hospital Universitario Central de Asturias, Oviedo, Spain

Received 23 July 2015; Revised 20 December 2015; Accepted 28 December 2015

Academic Editor: Hyeong Gon Yu

Copyright © 2016 Álvaro Fernández-Vega Sanz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. Serous retinal detachment SRD is a common anatomical complication associated with dome-shaped macula DSM and staphyloma margin in myopic patients. Here we described the anatomical and functional outcomes obtained with the use of oral spironolactone, a mineralocorticoid antagonist, in the management of myopic patients with SRD associated with DSM and staphyloma margin. Methods. We evaluated both eyes of twelve myopic patients with long-standing SRD associated with DSM or staphyloma margin. The patients were treated daily for six months with oral spironolactone 50 mg. Best-corrected visual acuity BCVA and central retinal thickness CRT, determined by optical coherence tomography, were evaluated on the first day and on monthly follow-up visits. Results. Pretreatment BCVA mean ± standard deviation was 0.406 ± 0.324 LogMAR, and posttreatment BCVA was 0.421 ± 0.354 LogMAR . Pretreatment CRT was 323.9 ± 78.6 μm, and after six months of treatment it was significantly lower, 291.2 ± 74.5 μm . There were no treatment-related complications. Conclusions. We evaluated a novel treatment for SRD associated with DSM and staphyloma margin in myopic patients. After six months of treatment with the mineralocorticoid antagonist spironolactone, the subretinal fluid and CRT were significantly reduced; however, there was no improvement in BCVA.





Autor: Álvaro Fernández-Vega Sanz, Carlos Mario Rangel, Eva Villota Deleu, Beatriz Fernández-Vega Sanz, and Ronald Mauricio Sánch

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados